Lineage Cell Therapeutics Reports Positive 36-Month Phase 1/2a Results for RG6501 in OpRegen Trial
ByAinvest
Tuesday, Sep 23, 2025 7:28 pm ET1min read
LCTX--
Lineage Cell Therapeutics, Inc. (LCTX) reported positive 36-month Phase 1/2a results for its OpRegen therapy, showing sustained vision improvements in patients with geographic atrophy, a form of age-related macular degeneration. The company also treated its first chronic spinal cord injury patient in a new OPC1 trial and partnered with William Demant Invest A/S to develop a cell transplant program for sensorineural hearing loss. LCTX holds $42.3 million in cash and continues to invest in R&D and manufacturing capabilities.
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
ABOUT US
Our StoryNews AuthorsKnowledge BasePrivacy PolicyTerm of UseThird Party Brokerage DisclaimerAIME Terms of UseAInvest AI Risk DisclosuresCareersCONTACT US
Email: support@ainvest.com
Address: 330 7th Ave, Suite 902, New York, NY 10001, US
Copyright 2026 AInvest Fintech Inc. All rights reserved.
Comments
No comments yet